APPLICATION
ANDA209433
TYPE
ANDA
ORIGINAL APPROVAL
2020-01-03
LATEST ACTION
2023-05-19
ROUTE
ORAL
DOSAGE FORM
TABLET, FOR SUSPENSION
MARKETING STATUS
Prescription
Products
DEFERASIROXPrescription
DEFERASIROX 250MG · TABLET, FOR SUSPENSION · ORAL
DEFERASIROXPrescription
DEFERASIROX 500MG · TABLET, FOR SUSPENSION · ORAL
DEFERASIROXPrescription
DEFERASIROX 125MG · TABLET, FOR SUSPENSION · ORAL
Approval history
2023-05-19Labeling · Supplement 1 · standardAP
2023-05-19Labeling · Supplement 2 · standardAP
2020-01-03UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.